268 results match your criteria: "Urticaria Dermographism"
Features of chronic urticaria after COVID-19 mRNA vaccine over time.
Commun Med (Lond)
November 2024
Division of Immunology and Allergy, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.
Article Synopsis
- Chronic urticaria (CU) has been reported in some individuals after receiving the Moderna mRNA-1273 vaccine, prompting this study to analyze its onset related to COVID-19 vaccination, SARS-CoV-2 infection, and atopy factors.
- A study involving 50 individuals with CU and 135 without CU assessed the immunological responses and the presence of anti-vaccine IgE through surveys and blood tests conducted in 2022 and 2023.
- Results indicated that post-vaccination CU typically appears about 10 days after the Spikevax booster, especially affecting middle-aged women, with 53% of cases still active in 2023; however, some patients tolerated additional doses without worsening their symptoms,
Erythema, localized edema and heat vs forearm perimeter increase. Time to revise the consensus recommendations on the vortex provocation test in vibratory urticaria-angioedema?
Actas Dermosifiliogr
November 2024
Universidad de Castilla-La-Mancha, Toledo, España; Servicio de Dermatología. Hospital Universitario de Guadalajara, Guadalajara, España; Servicio de Dermatología. Hospital Universitario Fundación Jiménez Díaz, Madrid, España; Departamento de Medicina y Especialidades Médicas. Facultad de Medicina y Ciencias de la Salud. Universidad de Alcalá, Alcalá de Henares, España. Electronic address:
Background And Objective: Diagnosis of vibratory urticaria/angioedema is established after performing the vortex provocation test. There is current consensus on measuring the forearm perimeter after running such test to define a positive response to it.
Material And Method: We evaluated the frequency of prior symptoms following vibratory stimuli in volunteers using a questionnaire, response to the vortex provocation test in the same volunteers (increase in forearm perimeter, erythema, localized edema, heat, and pruritus), interrater reliability, and correlation between the scores obtained in the questionnaire and response to the test.
Eating increases disease activity in pediatric patients with symptomatic dermographism.
Allergy Asthma Proc
November 2024
Chronic Skin Diseases Unit, Department of Dermatology, Urticaria Center of Reference and Excellence, Kayseri City Education and Research Hospital, University of Health Sciences, Kayseri, Turkey.
Symptomatic dermographism (SD) is the most common form of chronic inducible urticaria. SD disease activity increases with food intake in adult patients. Whether this is also so in children with SD is currently unknown.
View Article and Find Full Text PDFKey differences between chronic inducible and spontaneous urticaria.
Front Allergy
October 2024
Division of Allergy, University Clinic of Respiratory and Allergic Diseases Golnik, Golnik, Slovenia.
Introduction: The latest international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for urticaria recommends limited laboratory testing for chronic spontaneous urticaria (CSU) and selective testing for only certain chronic inducible urticaria (CIndU) subtypes, though the rationale for these recommendations is poorly explained. This study aimed to improve the understanding of CIndU subtypes by comprehensively comparing their demographic, clinical, and laboratory characteristics with those of the better-characterized CSU.
Methods: We conducted a retrospective analysis of 567 patients (median age 41 years, 67% female) diagnosed with CSU, symptomatic dermographism (SD), cold urticaria (ColdU), cholinergic urticaria (CholU), and delayed pressure urticaria (DPU).
Decoding the variability in clinical and laboratory profiles of Chronic Inducible Urticaria vs. Chronic Spontaneous Urticaria - a retrospective study from a tertiary care center.
Arch Dermatol Res
October 2024
Department of Dermatology, Venereology, and Leprology, Postgraduate Institute of Medical Education and Research, Sector12, Chandigarh, 160012, India.
Article Synopsis
- Chronic inducible urticaria (CIndU) lasts longer than 6 weeks and is triggered by specific factors, but research on its severity and treatment is limited compared to chronic spontaneous urticaria (CSU).
- A study reviewed data from 222 CIndU patients and 226 CSU controls, finding that both groups were similar in age and gender, but CIndU patients had significantly lower CRP levels and a poorer quality of life score (CU-QOL).
- CIndU patients required more frequent antihistamine adjustments (80% vs. 52% in CSU) and took longer to achieve remission, averaging 60 days compared to 27.77 days for CSU patients.
Chronic Urticaria in Children: A Single-Center Retrospective Study From Turkey.
Clin Pediatr (Phila)
September 2024
Department of Dermatology, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.
Article Synopsis
- - The study aimed to explore the causes and characteristics of chronic urticaria (CU) in children under 18, finding that a majority of participants were aged 12 or older.
- - Chronic spontaneous urticaria (CSU) was the most common type, affecting 75% of the participants, while 18.5% also experienced angioedema; however, 56.5% had no identifiable cause for their urticaria.
- - Infections were the main identified trigger, accounting for 29.8%, with dental issues being the most common infection related to CU; the prevalence of chronic urticaria increased with age among the children studied.
New insights into chronic inducible urticaria.
Curr Allergy Asthma Rep
August 2024
Institute of Allergology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health, 10178, Berlin, Germany.
Article Synopsis
- Chronic inducible urticaria (CIndU) is a difficult-to-manage condition marked by recurring hives and swelling, triggered by specific factors, and recent research has focused on understanding its causes and improving treatment options.
- New methods for evaluating patient experiences have been developed, highlighting the significant impact CIndU has on quality of life and enabling better diagnosis through provocation tests for different subtypes.
- Currently, second-generation non-sedating antihistamines are the primary recommended treatment, but they often fall short; however, off-label use of omalizumab shows promise, along with other emerging therapies being researched for future options.
Chronic Inducible Urticaria.
Immunol Allergy Clin North Am
August 2024
Department of Dermatology and Venerology, Kepler University Hospital, Urticaria Center of Excellence and Reference (UCARE), Linz, Austria; Center for medical research, Johannes Kepler University, Linz, Austria; Institute of Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany. Electronic address:
Article Synopsis
- * Diagnosis relies on patient history, trigger tests, and self-reported symptoms.
- * Current treatments mirror those for chronic spontaneous urticaria but are largely off-label; new targeted therapies are in clinical trials due to the significant impact on patients.
Unveiling Treatment Response Predictors in Predominant Subtypes of Chronic Inducible Urticaria.
Int Arch Allergy Immunol
November 2024
Department of Dermatology, Koc University School of Medicine, Istanbul, Turkey.
Article Synopsis
- * A study involving 423 patients found that treatment response rates to antihistamines (AH) and omalizumab were generally higher in CIndU than in other chronic urticaria types, especially for symptomatic dermographism (SD) and cold urticaria.
- * Factors such as longer disease duration, presence of angioedema, and lower baseline urticaria control scores can help predict how well patients with CIndU will respond to antihistamine treatment.
Shedding light on dermographism: a narrative review.
Int J Dermatol
August 2024
Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China.
Article Synopsis
- Dermographism is a type of chronic urticaria that appears as a raised line on the skin after scratching or friction, due to mast cell activation and histamine release.
- Diagnosing dermographism typically involves a medical history review and specific skin tests, along with tools like the Urticaria Control Test for assessing treatment effectiveness.
- First-line treatment includes nonsedating H1 antihistamines, with the option to increase the dosage or use omalizumab in unresponsive cases, but more research is needed on biomarkers for better understanding and managing the condition.
Functional brain alterations in symptomatic dermographism patients-An exploratory magnetoencephalography study.
Exp Dermatol
February 2024
Amsterdam UMC Location Vrije Universiteit Medical Center (VUmc) Amsterdam, Neurology, Amsterdam, The Netherlands.
Article Synopsis
- Symptomatic dermographism (SD) is a type of skin condition that causes hives and itching when the skin is stroked, and this study used magnetoencephalography (MEG) to explore the brain's role in this condition.
- Twelve SD patients and fourteen control participants were tested for itch response and brain activity after exposure to histamine and skin stroking, revealing that SD patients reported greater itch levels than controls.
- The study found no major brain activity differences between groups but observed notable changes in brain wave patterns, suggesting that SD may involve abnormal itch processing linked to the central nervous system.
Severe symptomatic late onset dermographism after mRNA COVID-19 vaccine.
Ital J Dermatol Venerol
February 2024
Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
A Case-Control Study Comparing the General Characteristics of Patients with Symptomatic Dermographism and Chronic Spontaneous Urticaria: Is Atopy a Risk Factor for Symptomatic Dermographism?
Int Arch Allergy Immunol
March 2024
Department of Allergy and Clinical Immunology, Başakşehir Çam and Sakura City Hospital, Istanbul, Turkey.
Article Synopsis
- Symptomatic dermographism (SDerm) is a common type of chronic urticaria, but there's limited information on its features and related conditions; this study aimed to compare it with chronic spontaneous urticaria (CSU).
- The research analyzed data from 361 patients (220 with CSU, 141 with SDerm) and found higher rates of asthma, allergic rhinitis, and thyroid disease in the SDerm group, along with lower disease duration and antihistamine use.
- The study concluded that patients with SDerm show a higher prevalence of atopic diseases and sensitivities to specific allergens compared to those with CSU, suggesting the need for broader studies to confirm these findings.
A comparative analysis of chronic inducible urticaria in 423 patients: Clinical and laboratory features and comorbid conditions.
J Eur Acad Dermatol Venereol
March 2024
Department of Dermatology, Koc University School of Medicine, Istanbul, Turkey.
Article Synopsis
- * A study analyzed 423 CIndU patients, revealing that most were isolated CIndU, with symptomatic dermographism (SD) being the most common subtype, followed by cold urticaria (ColdU) and cholinergic urticaria (ChoU).
- * Findings indicate that patients with CSU plus CIndU are generally older, experience more severe symptoms, and have additional comorbid conditions compared to those with isolated CIndU, highlighting the differences in severity and characteristics
Dermographism from N95 surgical masks contributing to facial rashes in healthcare workers.
Contact Dermatitis
August 2023
Occupational Dermatology Research and Education Centre (ODREC), Skin Health Institute, Carlton, Victoria, Australia.
Symptomatic dermographism induced by oral minocycline: A report of four cases.
J Dermatol
August 2023
Department of Dermatology, Southwest Hospital, Army Medical University, Chongqing, China.
Article Synopsis
- Symptomatic dermographism (SD) is a common type of skin condition that can be triggered by external factors, but its causes are not often documented.
- Four young women developed SD after taking minocycline for acne or rosacea, with symptoms appearing 2-3 weeks after starting the medication.
- The SD symptoms resolved completely one month after discontinuing minocycline, indicating a potential link between the drug and the condition, prompting the need for further research to confirm this association and understand the mechanisms involved.
Comparison of Omalizumab Treatment Response in Patients with Chronic Spontaneous Urticaria and Symptomatic Dermographism: A Single-Center Retrospective Study.
Int Arch Allergy Immunol
March 2023
Department of Allergy and Clinical Immunology, Başakşehir Çam and Sakura City Hospital, Istanbul, Turkey.
Article Synopsis
- - Omalizumab, an anti-IgE monoclonal antibody, is effective for treating chronic spontaneous urticaria (CSU) and has been evaluated for its impact on symptomatic dermographism (SDerm) due to limited existing research on the latter.
- - A retrospective study assessed treatment responses from 116 patients (92 with CSU and 24 with SDerm) using the urticaria control test (UCT) and dermatology quality of life questionnaire (DLQI), finding no significant difference in omalizumab effectiveness between the two groups.
- - Overall, both patient groups showed significant improvement post-treatment, with notable increases in UCT scores and decreases in DLQI scores, signaling enhanced quality of life and
Eating Increases and Exercise Decreases Disease Activity in Patients With Symptomatic Dermographism.
J Allergy Clin Immunol Pract
March 2023
Urticaria Center of Reference and Excellence, Institute of Allergology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany. Electronic address:
Article Synopsis
- Eating can worsen symptoms of symptomatic dermographism, a common chronic skin condition, but the extent of this effect is not fully understood.
- The study assessed the impact of exercising and carbohydrate-rich foods on disease severity among 75 patients, finding that a majority experienced negative effects from eating.
- Results indicated that exercise significantly reduced skin reactions in most participants and helped protect many from food-induced symptom worsening, particularly when exercised after eating.
Natural history and clinical course of patients with dermographism in a tropical country: a questionnaire-based survey.
Asia Pac Allergy
October 2022
Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Article Synopsis
- Dermographism is a common skin condition characterized by hives that appear after skin is scratched or rubbed, and this study focuses on its impact on Thai patients.
- A 2021 survey involving 2,456 respondents found that 1,900 had symptomatic dermographism (SD), with women more frequently affected than men, and the average onset age was around 15-16 years.
- Many patients experience moderate itching, often let the hives resolve on their own, and commonly self-medicate with over-the-counter antihistamines, highlighting the condition's impact on their quality of life.
Delayed onset urticaria and symptomatic dermographism following COVID-19 booster vaccination: A case series.
Clin Transl Allergy
November 2022
Department of Clinical Genetics, Odense University Hospital, Odense, Denmark.
Anti-KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria.
Allergy
May 2023
Institute of Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Article Synopsis
- Chronic inducible urticaria (CIndU), a condition caused by mast cell-mediated allergic reactions, can be effectively treated with barzolvolimab, a humanized antibody that inhibits mast cell activation by stem cell factor (SCF).* -
- In a trial involving patients unresponsive to antihistamines, one dose of barzolvolimab resulted in significant mast cell depletion and reduced levels of tryptase, leading to improved urticaria control and quality of life.* -
- The treatment was well tolerated with mostly mild side effects, and 95% of patients showed complete responses within 12 weeks, indicating strong potential for barzolvolimab in treating mast cell-related disorders.*
A survey on subtypes and clinical characteristics of 1061 patients with urticaria in the primary care institutes in Japan.
J Dermatol
December 2022
Department of Dermatology, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Article Synopsis
- The study focused on the prevalence and characteristics of urticaria (hives) among patients who visited primary care clinics in Japan, with a sample size of 1,061 participants.
- The most common subtype was chronic spontaneous urticaria (CSU), which was more frequent in females and tended to increase with age.
- Additionally, the evaluation of urticaria control showed poor management in patients who had CSU along with other urticaria subtypes compared to those with CSU alone.
Evidence for histamine release in chronic inducible urticaria - A systematic review.
Front Immunol
August 2022
Institute of Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Article Synopsis
- * A detailed literature review of studies was conducted, narrowing down from 3,882 articles to 107 relevant studies that examined histamine levels following various triggers in different types of CIndU.
- * The findings confirm that while histamine is an important factor in CIndU, it is not the only one involved, as there is often a weak correlation between histamine levels and symptom severity, indicating other mediators may also be significant.
Integrative lipidomic features identify plasma lipid signatures in chronic urticaria.
Front Immunol
August 2022
Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China.
Article Synopsis
- Chronic urticaria (CU) is a skin disease driven by mast cells, and researchers studied the lipid profiles of CU patients compared to healthy individuals to understand its underlying mechanisms.
- Significant changes in glycerophospholipids, particularly increased phosphatidylserine (PS) and phosphatidylethanolamine (PE), along with a decrease in phosphatidylcholine (PC), were observed in CU patients, with specific lipid levels correlating with urticaria severity and quality of life.
- The study identified different CU subtypes based on lipid profiles and suggested that supplementation with PC could help reduce immune responses in mast cells, offering new insights into potential treatments for CU.